Sevion is exploring opportunities to capitalize on our internally-generated assets, intellectual property and technology platforms, as well as to in-license clinical stage assets that fit our pipeline. The Company is conducting cell surface screening of its spatially addressed antibody libraries to identify a portfolio of highly differentiated product candidates for both internal and partnered programs. Our approach, applicable in nearly every therapeutic area, creates access to high-impact cell surface drug targets like multispanning membrane proteins that are inaccessible to conventional antibody technologies and scaffolds. We are also working with potential collaborators to leverage the intellectual property around our nanocage delivery technology, which has broad applications across human health, agriculture and biofuels.

For more information about partnering with Sevion, please contact: